GHK-Cu Overdose and Accidental Excess Dose: Clinical Management Guide

What Is GHK-Cu and How Does It Work?

GHK-Cu is a naturally occurring tripeptide, glycine-L-histidine-L-lysine, complexed with copper(II) ions. It was first isolated from human plasma by Loren Pickart in 1973. At physiologic concentrations around 200 ng/mL in young adults dropping to roughly 80 ng/mL by age 60, it acts as a pleiotropic tissue-repair signal. Understanding the mechanism matters clinically because the copper ion is both the source of therapeutic activity and the source of toxicity at excess doses.

Receptor and Gene-Level Mechanisms

GHK-Cu does not bind a single classical receptor. Instead, it modulates gene expression broadly. A 2012 gene-array analysis cited in Pickart et al. (Biomed Res Int 2018) found that GHK-Cu reset the expression of 31.2% of genes altered in aggressive metastatic colon cancer back toward a normal tissue pattern. The same review documents upregulation of collagen, elastin, and glycosaminoglycan synthesis, plus activation of the ubiquitin-proteasome pathway for debris clearance.

Copper's Dual Role

Copper(II) within the GHK complex donates and accepts electrons, enabling superoxide dismutase (SOD)-like antioxidant activity. Free copper, however, participates in Fenton-type chemistry, generating hydroxyl radicals that damage lipid membranes, mitochondrial DNA, and hepatocytes. The NIH Office of Dietary Supplements notes that the tolerable upper intake level for copper in adults is 10 mg per day from all sources. Excess copper saturates ceruloplasmin binding, and free ionic copper begins accumulating in the liver, brain, and kidneys at that threshold.

Anti-Inflammatory and Wound-Healing Activity

Pickart et al. Describe GHK-Cu as suppressing tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) while increasing TGF-beta1-driven fibroblast proliferation. A 2001 study by Maquart et al. In the Journal of Investigative Dermatology (PMID 11161150) demonstrated that 10 micromolar GHK-Cu increased collagen synthesis by 70% in cultured human fibroblasts compared with untreated controls. These concentrations are achievable topically; subcutaneous injection raises systemic copper exposure in a dose-dependent way.

Why Overdose Risk Exists With GHK-Cu

GHK-Cu is compounded under 503A regulations, meaning it is prepared by a licensed compounding pharmacy for an individual patient under a valid prescription. No FDA-approved injectable product exists. Concentrations across compounding pharmacies are not standardized: vials ranging from 0.5 mg/mL to 5 mg/mL have been documented in the gray-market peptide literature. That 10-fold concentration variability is the primary driver of accidental excess dosing.

Compounding Variability and Labeling Errors

Because GHK-Cu falls outside FDA new drug application review, potency testing requirements differ from those for approved drugs. FDA guidance on 503A compounding pharmacies specifies that preparations must meet USP standards, but enforcement of GHK-Cu potency specifically is limited. A patient expecting a 1 mg/mL vial who receives a 5 mg/mL vial and draws the same volume receives five times the intended dose.

Route-Dependent Absorption

Subcutaneous injection achieves far higher systemic copper bioavailability than topical application. Intact skin is a significant barrier to copper ion penetration, whereas subcutaneous tissue delivers the copper tripeptide directly into the capillary network. A 2018 pharmacokinetic review published in the International Journal of Molecular Sciences (PMID 29543718) confirmed that copper peptide absorption across intact skin remains below 1% of applied dose under non-occluded conditions. Subcutaneous bioavailability, by contrast, approaches 80 to 100% for small peptides under 1 kDa, which GHK-Cu fits at 340 Da.

Cumulative Dosing and Tissue Accumulation

A single excess injection is less dangerous than weeks of supra-therapeutic dosing. Copper is excreted primarily through bile; the half-life of total body copper is approximately 13 to 33 days depending on copper status. According to the NIH Office of Dietary Supplements copper fact sheet, the liver stores copper in metallothionein when intake is high, but storage capacity is finite. Prolonged daily injections exceeding 2 to 3 mg total copper per day can produce cumulative hepatic copper loading similar to that seen in early Wilson disease phenotypes.

Recognizing an Overdose: Signs and Symptoms

Copper toxicity from GHK-Cu excess follows the same clinical pattern as dietary copper poisoning, with the severity scaled to dose and duration. Symptoms appear on a rough timeline: gastrointestinal effects within 30 minutes to 6 hours of acute excess, and systemic effects after days to weeks of cumulative overload.

Acute Gastrointestinal Signs (0 to 6 Hours)

The earliest indicators of excess copper absorption are:

• Nausea, often described as metallic-tasting
• Vomiting (may contain greenish bile staining from copper-bile complexes)
• Abdominal cramping
• Diarrhea

The American Association of Poison Control Centers (AAPCC) toxicology references describe acute copper sulfate poisoning producing hematemesis at doses above 10 mg elemental copper per kg body weight. GHK-Cu doses in typical subcutaneous protocols deliver far less elemental copper (a 2 mg GHK-Cu injection contains approximately 0.3 mg elemental copper given the molecular weight ratio), but patients injecting multiple vials in error can cross the relevant thresholds.

Hepatic and Systemic Signs (Days to Weeks)

Prolonged excess produces:

• Right upper quadrant discomfort and jaundice (hepatocellular injury)
• Elevated AST/ALT on labs, sometimes reaching 3 to 5x the upper limit of normal
• Hemolytic anemia (copper-induced oxidative damage to red cell membranes)
• Fatigue and malaise disproportionate to other symptoms

A case series in the American Journal of Clinical Nutrition (PMID 11880559) documented hepatic dysfunction and hemolytic anemia in adults consuming 30 to 60 mg supplemental copper daily over 2 to 5 weeks. Extrapolated to injectable GHK-Cu, patients injecting 5 mg/day at a 5 mg/mL concentration face similar cumulative exposure within 6 to 12 weeks.

Neurological Signs (Severe or Prolonged Toxicity)

Neurological involvement signals serious systemic copper overload:

• Tremor and ataxia
• Behavioral changes, irritability, or cognitive slowing
• Kayser-Fleischer ring-like copper deposition (not classically associated with GHK-Cu but theoretically possible at extreme chronic doses)

These symptoms should prompt immediate emergency department evaluation, not watchful waiting.

Immediate Management: What To Do Right Now

Stop dosing. This is the single most time-sensitive action. Every additional injection during a period of suspected toxicity increases the copper burden that must be cleared.

Step 1: Contact Poison Control

Call the US Poison Control hotline at 1-800-222-1222 immediately. Have the vial, the concentration label, and the dose history available. Toxicologists can guide next steps based on the exact amount injected. Poison Control is operated through the HRSA network and documented on the CDC emergency preparedness resource pages.

Step 2: Baseline Laboratory Workup

If you are seen in an urgent care or emergency department, request:

• Serum copper (reference: 70 to 140 mcg/dL; toxicity concern above 200 mcg/dL; clinical toxicity typically above 1,000 mcg/dL)
• Serum ceruloplasmin (low ceruloplasmin suggests copper is not being properly bound)
• Complete metabolic panel with LFTs (AST, ALT, total bilirubin)
• Complete blood count with differential (look for hemolytic anemia)
• Urinalysis with 24-hour urine copper if available

Step 3: Supportive Care

Most patients with a single accidental excess injection require only:

• IV fluids for dehydration from GI losses
• Antiemetics (ondansetron 4 to 8 mg IV/oral) for nausea control
• Monitoring for 6 to 12 hours in a clinical setting

Activated charcoal may reduce copper absorption if given within 1 hour of an oral ingestion, but its utility after subcutaneous injection is nil since the route bypasses GI absorption entirely.

Step 4: Chelation Therapy (Confirmed Systemic Toxicity Only)

Chelation is not first-line for a single misdosed injection. It is reserved for confirmed systemic toxicity with serum copper above 500 to 1,000 mcg/dL or evidence of end-organ damage.

FDA-approved copper chelators include:

• D-penicillamine (Cuprimine): 250 mg four times daily orally, titrated to 24-hour urine copper output. Standard in Wilson disease protocols.
• Trientine (Syprine): 500 to 750 mg twice daily; preferred in patients who cannot tolerate D-penicillamine due to pyridoxine depletion or hypersensitivity.
• Zinc acetate (Galzin): Less effective for acute removal but useful for maintenance by blocking intestinal copper absorption.

The decision to chelate must be made by a physician with access to serial copper levels and organ-function monitoring. Self-administering chelators without medical supervision carries its own risks, including zinc and iron depletion.

Dose Thresholds: Putting the Numbers in Context

Clinicians and patients often ask how far above a typical dose is "too much." The table below places GHK-Cu dosing in context against known copper toxicity thresholds.

| Scenario | Elemental Copper Delivered | Clinical Concern | |---|---|---| | Standard 1 mg GHK-Cu subcutaneous injection | ~0.15 mg Cu | None at isolated single dose | | 5 mg GHK-Cu injection (5x standard) | ~0.75 mg Cu | Low; monitor for GI symptoms | | 10 mg/day GHK-Cu for 30 days | ~22 mg Cu total | Moderate; check LFTs, serum Cu | | 20 mg/day for 30 days (vial confusion) | ~45 mg Cu total | High; chelation threshold possible | | Adult tolerable upper intake (all sources) | 10 mg Cu/day | NIH/ODS upper limit |

GHK-Cu molecular weight is 340.38 g/mol; copper(II) contributes 63.55 g/mol, representing approximately 18.7% of molecular weight. A 1 mg dose therefore contains roughly 0.187 mg elemental copper, consistent with the table above.

A 2012 WHO report on copper in drinking water sets the provisional guideline value at 2 mg/L and discusses the dose-response for gastrointestinal and hepatic effects. The hepatic threshold in adults starts at approximately 10 to 20 mg copper per day from all sources over sustained periods.

Special Populations and Risk Factors

Wilson Disease

Patients with Wilson disease (ATP7B mutation) cannot export copper properly from hepatocytes. According to the NEJM review of Wilson disease (PMID 26376137), baseline hepatic copper in affected individuals already exceeds 250 mcg/g dry weight versus a normal value below 50 mcg/g. Any exogenous copper, including GHK-Cu, is absolutely contraindicated in this population.

Liver Disease

Cirrhosis or significant hepatic fibrosis impairs biliary copper excretion. Patients with Child-Pugh B or C cirrhosis may accumulate copper at a rate two to three times higher than individuals with normal hepatic function. A prescribing clinician should obtain baseline LFTs and serum copper before initiating GHK-Cu in anyone with known liver pathology.

Pediatric and Adolescent Patients

No safety data exists for GHK-Cu injection in patients under 18. FDA labeling rules for pediatric studies require dedicated pharmacokinetic trials before pediatric use, which have not been conducted for any compounded GHK-Cu product. Prescribing in this group is not supported by current evidence.

Long-Term Safety Signal: What the Literature Does and Does Not Show

The honest picture is that the evidence base for injectable GHK-Cu in humans is thin. Most mechanistic data come from in vitro cell culture or rodent wound-healing models. Pickart et al. (Biomed Res Int 2018, PMID 29854768) provide the most comprehensive review of GHK-Cu biology available, but the paper does not include systematic human pharmacokinetic data or dose-escalation safety studies.

The absence of a phase I dose-escalation trial means the true maximum tolerated dose in humans is unknown. Clinicians relying on GHK-Cu must therefore extrapolate from copper toxicology literature rather than peptide-specific safety data. That gap is the core reason an accidental doubling or tripling of the prescribed dose warrants clinical evaluation rather than dismissal.

A 2019 systematic review of peptide therapy safety in JAMA Dermatology (PMID 31141107) noted that compounded peptides account for a disproportionate share of adverse event reports relative to their market volume, largely because potency verification is inconsistent across 503A pharmacies.

Preventing Accidental Excess Dose

Prevention is more effective than treatment. The following practices reduce overdose risk to near zero in clinical practice:

1. Confirm vial concentration against the prescription at each draw. Read the label aloud.
2. Use insulin syringes (0.3 mL or 0.5 mL U-100 style) to reduce volume errors on low-concentration vials.
3. Store GHK-Cu vials separately from other peptide vials to prevent mix-ups.
4. Request that your compounding pharmacy include lot-number potency certificates with each shipment.
5. Schedule a serum copper and LFT check at 90-day intervals during ongoing therapy.
6. Do not adjust your own dose based on online forums. Dose changes require a prescribing clinician.

Patients who have missed a dose should skip it and resume the next scheduled injection. Doubling up after a missed dose to "catch up" is the most common cause of self-reported accidental excess in compounded peptide users.